2,2-dimethoxyacetimidate de methyle | 135290-61-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 甲亚胺酸及其衍生物
• 英文名称: 2,2-dimethoxyacetimidate de methyle
• 英文别名: Methyl 2,2-dimethoxyacetimidate；methyl 2,2-dimethoxyethanimidate
• CAS: 135290-61-8
• 化学式: C₅H₁₁NO₃
• 分子量: 133.147
• InChiKey: GIKMYGRKJPKTLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  51.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,2-dimethoxyacetimidate de methyle 、 2-氨基-3-氨基甲基吡嗪 以 乙醇 为溶剂， 以50%的产率得到2-Dimethoxymethyl-3,4-dihydro-pteridine
  参考文献：
  名称：

  Synthèse et activité hypo-uricémiante de nouvelles ptéridines

  摘要：

  A series of new pteridines and 3,4-dihydropteridines with substitution in position 2, showed a hypouricemic activity in rats. After a single oral administration in this species, the hypouricemic effect of 2-(methoxymethoxymethyl)-3,4-dihydropteridine maleate 26b and 2-(2,2,2-trifluoroethoxymethyl)-3,4-dihydropteridine maleate 32b is as potent as that of 1H-pyrazolo[3,4-d]pyrimidin-4-ol (allopurinol). We showed a long-lasting fall of uricemia in further investigation of compound 26b; this fall can reach 80%. Compound 26b, unlike allopurinol, is not an in vitro xanthine oxidase inhibitor, but the ex vivo inhibition could be proved. It could be useful in the treatment of fout in human beings.

  DOI：

  10.1016/0223-5234(92)90144-p

文献信息

• Synthèse et activité hypo-uricémiante de nouvelles ptéridines
  作者：G Ferrand、H Dumas、J Decerprit

  DOI：10.1016/0223-5234(92)90144-p

  日期：1992.6

  A series of new pteridines and 3,4-dihydropteridines with substitution in position 2, showed a hypouricemic activity in rats. After a single oral administration in this species, the hypouricemic effect of 2-(methoxymethoxymethyl)-3,4-dihydropteridine maleate 26b and 2-(2,2,2-trifluoroethoxymethyl)-3,4-dihydropteridine maleate 32b is as potent as that of 1H-pyrazolo[3,4-d]pyrimidin-4-ol (allopurinol). We showed a long-lasting fall of uricemia in further investigation of compound 26b; this fall can reach 80%. Compound 26b, unlike allopurinol, is not an in vitro xanthine oxidase inhibitor, but the ex vivo inhibition could be proved. It could be useful in the treatment of fout in human beings.